News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Twinstrand Therapeutics Announces US FDA Approval Of Its IND Application For Clinical Development Of TST10088


10/19/2005 5:09:02 PM

BURNABY, B.C., July 27 /CNW/ - Twinstrand Therapeutics Inc. (Twinstrand) today announced that the United States Food and Drug Administration (US FDA) has approved its Investigational New Drug (IND) application for the clinical development of TST10088; a novel, proprietary and targeted prodrug being developed for the treatment of solid tumor forms of cancer.

Read at Canada NewsWire

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES